The third dose of the Pfizer / BioNTech vaccine has shown protection of the 95.6% against contagions of COVID-19 and behaves in a way “safe and tolerable”both companies reported this Thursday.
Pfizer and BioNTech conducted a study when the most contagious delta variant was on the rise in the world, and with people who had received the previous two doses eleven months ago.
This vaccine received authorization for emergency use in the US in mid-December, possibly involving volunteers who took part in the first serum trials.
“These results offer further evidence of the benefits of booster doses, as we try to keep people well protected against this disease.”Pfizer CEO Albert Bourla said in a joint statement.
The study was carried out on a sample of 10,000 people in the United States, Brazil and South Africa, half of them aged between 16 and 55 years and a quarter over 65 years.
BioNTech CEO Ugur Sahin said that these findings show that in addition to “global access to vaccines for all, booster vaccines could play an important role in supporting the containment of the pandemic and a return to normalcy. “.
This is the first clinical study that requires the protection of additional doses, after several investigations revealed that the potency of the first injections of this vaccine begins to dissipate after six months.
Last September, the US regulatory agency authorized the emergency use of the Pfizer / BioNtech booster dose for people over 65, with previous medical conditions or exposed to the coronavirus in their work.
The US hopes to begin administering doses of Pfizer / BioNTech to children between the ages of 5 and 11 from November, if authorities give the green light in the next few days.